Human CCL27/CTACK Biotinylated Antibody
R&D Systems, part of Bio-Techne | Catalog # BAF376
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Label
Antibody Source
Product Specifications
Immunogen
Phe25-Gly112
Accession # Q9Y4X3
Specificity
Clonality
Host
Isotype
Applications for Human CCL27/CTACK Biotinylated Antibody
Western Blot
Sample: Recombinant Human CCL27/CTACK (Catalog # 376-CT)
Human CCL27/CTACK Sandwich Immunoassay
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL27/CTACK
CCL27, also known as CTACK (cutaneous T cell-attracting chemokine), ALP, ILC, and ESkine, is a member of the CC family of chemokines (1). Mature human CCL27 is an 88 amino acid (aa) protein that shares 57% aa sequence identity with mouse and rat CCL27 (2). It shares 11% - 35% aa sequence identity with other human CC chemokines. An alternately spliced form of mouse CCL27, known as PESKY, is localized to the nucleus and promotes cellular migration (3). CCL27 is constitutively expressed by keratinocytes and is upregulated by inflammatory stimuli and in wounded skin (4-7). CCL27 binds the chemokine receptor CCR10, glycosaminoglycans in the extracellular matrix, sulfated tyrosine residues on PSGL-1, and determinants on the surface of fibroblasts and endothelial cells (5, 7-9). CCL27 cooperates with CCL17/TARC in inducing the migration of cutaneous lymphocyte antigen (CLA) positive memory T cells to the skin during inflammation (4, 6, 10-12). Endothelial cell-bound CCL27 can mediate the adhesion of those cells to CLA+ T cells (6). CCL27 also induces the migration of keratinocyte precursors from bone marrow to the skin, thereby promoting wound healing (7). In humans, serum CCL27 levels are elevated and correlate with disease severity in atopic dermatitis, psoriasis vulgaris, and mycosis fungoides (13-15).
References
- Kunkel, L. and E.C. Butcher (2002) Immunity 16:1.
- Ishikawa-Mochizuki, I. et al. (1999) FEBS Lett. 460:544.
- Gortz, A. et al. (2002) J. Immunol. 169:1387.
- Morales, J. et al. (1999) Proc. Natl. Acad. Sci. USA 96:14470.
- Homey, B. et al. (2000) J. Immunol. 164:3465.
- Homey, B. et al. (2002) Nat. Med. 8:157.
- Inokuma, D. et al. (2006) Stem Cells 24:2810.
- Jarmin, D. et al. (2000) J. Immunol. 164:3460.
- Hirata, T. et al. (2004) J. Biol. Chem. 279:51775.
- Vestergaard, C. et al. (2004) Exp. Dermatol. 13:551.
- Reiss, Y. et al. (2001) J. Exp. Med. 194:1541.
- Soler, D. et al. (2003) Blood 101:1677.
- Kakinuma, T. et al. (2003) J. Allergy Clin. Immunol. 111:592.
- Hijnen, D. et al. (2004) J. Allergy Clin. Immunol. 113:334.
- Fujita, Y. et al. (2006) Clin. Cancer Res. 12:2670.
Alternate Names
Gene Symbol
UniProt
Additional CCL27/CTACK Products
Product Documents for Human CCL27/CTACK Biotinylated Antibody
Product Specific Notices for Human CCL27/CTACK Biotinylated Antibody
For research use only